<DOC>
	<DOCNO>NCT00504543</DOCNO>
	<brief_summary>This study ass safety efficacy AEB071 combine everolimus CNI-free ( calcineurin inhibitor ) regimen renal transplant recipient .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability AEB071 Versus Cyclosporine Novo Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Inclusion criterion Male female patient 18 year old Recipients first kidney transplant decease living relate donor Exclusion criterion Need medication prohibit study Patients heart disease ( family history ) Patients donor HIV , Hepatitis B ( HBsAg ) Hepatitis C ( HCV ) positive Patients high immunological risk Patients history cancer Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Kidney transplant , AEB071</keyword>
</DOC>